Bioatla investor relations
WebMay 12, 2024 · BioAtla, Inc. May 12, 2024, 18:26 ET. SAN DIEGO, May 12, 2024 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB ), a global clinical-stage biotechnology … WebApr 3, 2024 · Investor FAQs; Email Alerts; Contact IR; SEC Filings Group. Filing year. Items per page. Filing date Form Description Filing Group View; 04/03/23: 4: Statement of changes in beneficial ownership of securities. 3,4,5. 0001209191-23-022427.pdf. 0001209191-23-022427.rtf ... BioAtla ® is a leading San ...
Bioatla investor relations
Did you know?
WebApr 6, 2024 · PFIZER INC. : Vorstellung des Unternehmens PFIZER INC., Aktionäre, Vorstände und Berufsbeschreibung, Finanzstärkerating, offizielle Mitteilungen, Kontaktdaten und ... WebThe Investor Relations website contains information about BioAtla, Inc's business for stockholders, potential investors, and financial analysts.
WebNov 4, 2024 · November 04, 2024 — 12:15 pm EDT. BioAtla, Inc. (BCAB) came out with a quarterly loss of $0.69 per share versus the Zacks Consensus Estimate of a loss of $0.77. This compares to loss of $0.68 ... WebDec 15, 2024 · BioAtla is registered under the ticker NASDAQ:BCAB . Their stock opened with $18.00 in its Dec 15, 2024 IPO. BioAtla is funded by 20 investors. Vivo Capital and Acuta Capital Partners are the most recent investors. BioAtla has a post-money valuation in the range of $500M to $1B as of Jul 16, 2024, according to PrivCo.
WebMar 24, 2024 · BioAtla, Inc. (NASDAQ:NASDAQ:BCAB) Q4 2024 Earnings Call Transcript March 23, 2024 4:30 PM ETCompany ParticipantsBruce Mackle - Investor Relations, … WebBioAtla ® is a leading San Diego-based biopharmaceutical company developing safer and more effective drugs for cancer. Its Conditionally Active Biologics ™ (CAB) platform exploits the unique microenvironment …
WebApr 11, 2024 · Which BioAtla major shareholders have been selling company stock? Of the 46 institutional investors that sold BioAtla stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: FMR LLC ($2.60M), Wellington Management Group LLP ($2.39M), Tang Capital Management LLC ($1.41M), …
WebNov 4, 2024 · BioAtla intends to use the net proceeds to be received by it in the offering, along with its existing cash and cash equivalents to fund our research and development … ウルガモス 種族値WebMay 4, 2024 · First Quarter Financial Results. Cash and cash equivalents as of March 31, 2024 were $219.4 million, compared to $245.0 million as of December 31, 2024. We expect current cash and cash equivalents ... palestra velo d\u0027asticoWebMay 4, 2024 · First Quarter Financial Results. Cash and cash equivalents as of March 31, 2024 were $219.4 million, compared to $245.0 million as of December 31, 2024. We … palestra velo d\\u0027asticoWebMar 23, 2024 · View Bioatla (www.bioatla.com) location in California, United States , revenue, industry and description. ... NASDAQ:BCAB) Q4 2024 Earnings Call Transcript March 23, 2024 4:30 PM ETCompany ParticipantsBruce Mackle - Investor Relations, LifeSci Advisors, LLCJay Short -... Mar 24, 2024. seekingalpha.com . ウルガモス育成論WebIf, at any time, you no longer wish to participate in householding and would prefer to receive a separate proxy statement and annual report, you may (1) notify your broker, (2) direct … palestra venditaWebMar 25, 2024 · Net loss for the full year ended December 31, 2024 was $35.9 million compared to a net loss of $29.8 million for the year 2024. About BioAtla, Inc. BioAtla is a global clinical-stage biotechnology ... ウルガモス 特性WebThe Investor Relations website contains information about BioAtla, Inc's business for stockholders, potential investors, and financial analysts. Skip to main navigation ... BioAtla is a clinical-stage biopharmaceutical company developing our novel class of highly specific and selective antibody-based therapeutics for the treatment of solid ... ウルガモス 育成論